Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oruka Therapeutics Inc ORKA

Healthcare Biotechnology
Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).


NDAQ:ORKA - Post by User

Oruka Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(240)
•••
Post by whytestockson Apr 22, 2024 11:45pm
84 Views
Post# 36002628

Expected US Company Earnings on Monday, April 22nd, 2024

Expected US Company Earnings on Monday, April 22nd, 2024
Just In: $ABIO Expected US Company Earnings on Monday, April 22nd, 2024Bank of Hawaii Corporation (BOH) is expected to report $0.92 for Q1 2024 Brown &amp; Brown Inc. (BRO) is expected to report $1.07 for Q1 2024 Independent Bank Group Inc (IBTX) is expected to report $0.57 for Q1 2024 Burnham Holdings Inc - Class A (BURCA) is expected to report for Q1 2...ABIO - Expected US Company Earnings on Monday, April 22nd, 2024

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities